menu
    • menu
    [{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Cytotoxic Drug","year":"2022","type":"Acquisition","leadProduct":"Arsenic Trioxide","moa":"TrxR1","graph1":"Immunology","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Bone Therapeutics \/ Medsenic","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Medsenic"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bimekizumab","moa":"IL-17A\/IL-17F receptor","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Filgotinib","moa":"JAK1","graph1":"Immunology","graph2":"Phase III","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Dapirolizumab Pegol","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCB Pharma S.A \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Biogen"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapirolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Lupus

                            Details : CDP7657 (dapirolizumab pegol), a novel Fc-free anti-CD40L drug candidate, investigated in people living with moderate-to-severe systemic lupus erythematosus (SLE).

                            Product Name : CDP7657

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 24, 2024

                            Lead Product(s) : Dapirolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Biogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB Receives CHMP Positive Opinion of Zilucoplan for the Treatment of Adults with Generalized Myasthenia Gravi...

                            Details : RA101495 (zilucoplan) is a once-daily SC, self-administered peptide inhibitor of complement component 5, which is investigated for the treatment of adults with generalized myasthenia gravis.

                            Product Name : Zilbrysq

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            September 15, 2023

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Galapagos

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galapagos Announces Topline Results From Phase 3 DIVERSITY Trial of Filgotinib In Crohn’s Disease

                            Details : Jyseleca (filgotinib) inhibits the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and some other conditions.

                            Product Name : Jyseleca

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rozanolixizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB Announces Rozanolixizumab BLA For The Treatment Of Generalized Myasthenia Gravis Filed With U.S. FDA And D...

                            Details : UCB7665 (Rozanolixizumab) is a subcutaneous monoclonal antibody targeting the neonatal Fc receptor (FcRn) for the treatment of adults with generalized myasthenia gravis who are antiacetycholine receptor or anti-muscle-specific tyrosine kinase antibody po...

                            Product Name : Rystiggo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 01, 2023

                            Lead Product(s) : Rozanolixizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimekizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB Receives Positive CHMP Opinions for Bimekizumab for the Treatment of Adults with Psoriatic Arthritis and A...

                            Details : Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both IL-17A and IL-17F, two key cytokines driving inflammatory processes, received positive CHMP opinion for psoriatic arthritis and axial spondyloarthr...

                            Product Name : Bimzelx

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 27, 2023

                            Lead Product(s) : Bimekizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Galapagos

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            Galapagos

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Galapagos Initiates Phase 3 Program with Filgotinib in Patients with Active Axial Spondyloarthritis

                            Details : Jyseleca (filgotinib) inhibits the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of active axial spondyloarthritis and some other conditions.

                            Product Name : Jyseleca

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 26, 2023

                            Lead Product(s) : Filgotinib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rozanolixizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious ...

                            Details : UCB7665 (rozanolixizumab) humanized mAb that specifically binds, with high affinity, to human neonatal FcRn. Designed to block the interaction of FcRn and IgG, accelerating the catabolism of antibodies and reducing the concentration of pathogenic IgG aut...

                            Product Name : Rystiggo

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 13, 2023

                            Lead Product(s) : Rozanolixizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            UCB Announces U.S. FDA Acceptance Of New Drug Application And EMA MAA Validation For Zilucoplan For The Treatm...

                            Details : Zilucoplan is a subcutaneous (SC), self-administered peptide inhibitor of complement component 5 (C5 inhibitor) for the treatment of adult patients with acetylcholine receptor antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG).

                            Product Name : Zilbrysq

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Bone Therapeutics

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            Bone Therapeutics

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acqui...

                            Details : The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Medsenic

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimekizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, No...

                            Details : Bimzelx (bimekizumab) is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

                            Product Name : Bimzelx

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 11, 2022

                            Lead Product(s) : Bimekizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth